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We have shown that cisplatin inhibits fatty acid oxidation,
and that fibrate treatment ameliorates renal function by
preventing the inhibition of fatty acid oxidation and proximal
tubule cell death. Urine samples of mice treated with single
injection of cisplatin (20 mg/kg body weight) were collected
for 3 days and analyzed by 1H—nuclear magnetic resonance
(NMR) spectroscopy. In a separate group, urine samples of
mice treated with peroxisome proliferator-activated receptor-a
(PPARa) ligand WY were also analyzed by NMR after 2 days of
cisplatin exposure. Biochemical analysis of endogenous
metabolites was performed in serum, urine, and kidney
tissue. Electron microscopic studies were carried out to
examine the effects of PPARa ligand and cisplatin. Principal
component analysis demonstrated the presence of glucose,
amino acids, and trichloacetic acid cycle metabolites in the
urine after 48 h of cisplatin administration. These metabolic
alterations precede changes in serum creatinine. Biochemical
studies confirmed the presence of glucosuria, but also
demonstrated the accumulation of nonesterified fatty acids,
and triglycerides in serum, urine, and kidney tissue, in spite
of increased levels of plasma insulin. These metabolic
alterations were ameliorated by the use of PPARa ligand.
Electron microscopic analysis confirmed the protective effect
of the fibrate on preventing cisplatin-mediated necrosis of
the S3 segment of the proximal tubule. Our study shows that
cisplatin-induces a unique NMR metabolic profile in urine of
mice that developed acute renal failure, and confirms the
protective effect of a fibrate class of PPARa ligands. We
propose that the injury-induced metabolic profile may be
used as a biomarker of cisplatin-induced nephrotoxicity.
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Previous studies have documented the presence of glucose
intolerance and insulin resistance, as metabolic abnormalities
that coexist with the development of acute renal failure
(ARF).1–5 The role of the kidney on the development of
systemic metabolic alterations that accompany ARF has not
been previously examined. In previous work, we and others
have described the accumulation of free fatty acids and toxic
long chain fatty acid metabolites in freshly isolated proximal
tubules subjected to hypoxic injury, and in kidney tissue
of animals subjected to ischemia/reperfusion injury. 6–9
We also documented the activation of intracellular
calcium-independent phospholipase A2,
10,11 and the inhibi-
tion of mitochondrial fatty acid oxidation as potential
mechanism(s) responsible for the accumulation of free fatty
acids in ischemic ARF.12,13
Recent work by Zager et al14,15 suggests that in addition to
fatty acid accumulation, ARF is also accompanied by the
accumulation of triglycerides (TG) and cholesterol as part of
a ‘renal stress response’ to injury. We have found that the
inhibition of mitochondrial and peroxisomal fatty acid
oxidation during ARF results from decreased DNA-binding
activity of the nuclear receptor peroxisome proliferator-
activated receptor-a (PPARa) to its target genes, and from
reduced expression of its tissue-specific coactivator peroxi-
some proliferator activated receptor gamma-coactivator-
1a.16,17 In addition, we recently demonstrated that in the
ischemia/reperfusion injury and cisplatin models of ARF, the
use of PPARa ligands such as fibrates ameliorates proximal
tubule injury and renal function only in wild-type and not in
PPARa-null mice, by directly inhibiting cellular mechanisms
leading to apoptosis and necrosis of the proximal tubule.18–21
In addition to our work, experimental evidence from other
laboratories also support the role of PPARa as an important
modulator of metabolic abnormalities associated with the
metabolic syndrome.22,23 PPARa is mainly expressed in the
liver, kidney, muscle, and heart tissue,24 and it regulates many
genes involved in the transport and oxidation of fatty acids.
Ligands of PPARa include long chain fatty acids, eicosanoids,
and hypolipidemic drugs such as fibrates. It has been well
documented that fibrates lower plasma TG levels and
promote elevation of high-density lipoprotein-cholesterol
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concentrations.25 Therefore, PPARa is a potential candidate
that may influence the risk of developing the metabolic
syndrome. Our previous work underscores the importance of
PPARa on restoring fatty acid oxidation during ARF;
however, our most recent studies suggest an additional role
for this proximal tubule nuclear receptor in improving
glucose utilization via regulation of pyruvate dehydrogenase
complex (PDC) enzyme activity and pyruvate dehydrogenase
kinase-4 in renal tissue.18 Using the model of cisplatin-
induced ARF, we found that the inhibition of renal PDC
enzyme activity preceded the inhibition of renal fatty acid
oxidation.18 PDC is a mitochondrial enzyme responsible for
the conversion of pyruvate to acetyl coenzyme A CoA under
normal conditions. Inhibition of PDC during ARF is
accompanied by increased expression and activity of pyruvate
dehydrogenase kinase-4. As normal kidney tissue utilizes
three carbon molecules such as acetyl CoA for the generation
of ATP from glucose, this observation suggests that inhibition
of glucose metabolism is affected early in the course of ARF.
To further examine the metabolic alterations that occur in
ARF, we have used high-resolution 1H-nuclear magnetic
resonance (NMR) spectroscopy with pattern recognition to
evaluate the metabolic profile of urine samples obtained from
mice that developed ARF after a single dose of cisplatin. Our
studies detected the early presence of metabolic abnormalities
including glucosuria, aminoaciduria, as well as the presence
of trichloroacetic acid cycle metabolites in urine within the
first 24 h of cisplatin administration. The presence of this
metabolic profile precedes the rise in serum creatinine and
blood urea nitrogen (BUN) that occurs 3 days after cisplatin
exposure. Serial biochemical determinations performed on
body fluids of mice treated with cisplatin confirmed the early
rise of serum glucose, fatty acids, and TG as well as increased
levels of glucose and fatty acids in urine and the accumula-
tion of glucose, fatty acids, and TG in kidney tissue.
Pretreatment with WY, a fibrate class of PPARa ligand,
prevented the rise of glucose, fatty acids, and TG in serum
and urine, prevented the accumulation of glucose, fatty acids,
and TG in kidney tissue and protected mice treated with
cisplatin. Therefore, our study demonstrates that compared
to mice treated with saline, cisplatin produced: (1) a unique
NMR metabolic profile in urine of mice that developed ARF,
(2) systemic metabolic alterations including an early rise of
serum glucose, nonesterified fatty acid (NEFA), and TG, as
well as accumulation of these metabolites in kidney tissue,
and (3) confirms the protective effect of a fibrate class of
PPARa ligands. These effects are likely the result of injury-
induced alterations in metabolism that are reversed by
PPARa ligands. We propose that the injury-induced meta-
bolic profile may be used as a biomarker of kidney injury.
RESULTS
Protective effects of PPARa ligand on cisplatin-induced ARF
Kidney function was monitored by measuring BUN and
serum creatinine for 3 days after intraperitoneal injection of
saline (groups control and WY) or cisplatin (groups cisplatin
and cisplatinþWY), Figure 1a and b present the changes on
BUN and creatinine in mice treated with saline (control),
cisplatin, and with WY in the presence of cisplatin. Mice
treated with a regular diet and cisplatin developed ARF at day
3 (BUN went up from 28 to 135 mg/dl, and creatinine went
up from 0.2 to 1.2 mg/dl). The group of mice that received
the WY diet and cisplatin did not develop significant ARF
when compared with mice treated with cisplatin alone (BUN
went from 24 to 32 mg/dl, and creatinine was unchanged at
0.2 mg/dl after 3 days of cisplatin administration). By
contrast, the protective effect of the ligand was lost in the
PPARa-null mice (/). PPARa-null mice (/) pretreated
with a WY diet before cisplatin administration developed
ARF at day 3. BUN went from 30 mg/dl at day 1 to 186 mg/dl
at day 3, and creatinine went from 0.3 mg/dl at day 1 to
1.5 mg/dl at day 3.
Electron microscopy studies
Changes in kidney morphology are shown in Figure 2.
There were no structural changes in the deep cortex of
kidneys from control animals. As can be seen in Figure 2a,
the S3 segment of proximal tubules contained regularly
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Figure 1 | Effect of fibrate WY-14643 (WY) on renal function in
mice after single dose of cisplatin. Mice were fed with either a
regular diet or a diet containing 0.1% WY for 7 days before cisplatin
administration, as described in Materials and Methods. BUN and
creatinine levels were measured at day 1, 2, and 3 after saline
(control)-, cisplatin-, or cisplatinþWY-treated mice. Bars correspond
to means7s.e. of at least six independent experiments under each
condition. (a) and (b) Changes in BUN and creatinine levels,
respectively, after saline or cisplatin administration in PPARa
wild-type mice. *Po0.005 when animals were compared with
control by unpaired Student’s t-test.
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Figure 2 | Electron microscopy of mouse kidney. Representative
electron micrographs of the deep cortex from kidneys of (a) control,
(b) cisplatin, and (c) fibrateþ cisplatin-treated mice. S3: proximal
tubules; T: thick ascending limbs, CD: collecting duct. Bar B50mm.
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arranged brush-border microvilli and intact cell cytoplasm
with abundant mitochondria. The thick ascending limbs and
collecting ducts were well preserved. Figure 2b shows the
major morphologic damage that occurs 3 days after cisplatin
treatment. The S3 segments of the proximal tubules were
extensively necrotic, the tubular basement membrane was
often denuded and heavily damaged, some of them revealing
necrotic cells with remnants of brush-border microvilli
(arrowheads) and apoptotic cells, desquamated into the
tubular lumen; at other sites, it was covered by very thin
processes of epithelial cells, which display short irregular
microvilli (arrows); thick ascending limb profiles are mostly
intact (whereas in many CD profiles the epithelium is
detached from the tubular basement membrane – not seen in
this picture). The morphologic kidney damage caused by
cisplatin was completely prevented in mice pretreated with
fibrate. As shown in Figure 2c, the S3 segments of proximal
tubules contained intact cytoplasmic and brush-border
morphology occasionally, a few desquamated cells were
visible in the lumen and apoptotic cells were rarely seen
among intact epithelial cells (not seen in this picture).
Accumulation of intracellular neutral lipids in kidney tissue of
cisplatin-treated mice
Our recent in vitro studies in proximal tubular cells in culture
exposed to cisplatin showed an increased accumulation of
intracellular fatty acids, which precedes the development of
proximal tubule cell death.21 Therefore, in the present study,
we examined whether intracellular lipids accumulate in vivo
in kidney tissue by performing intracellular stain of neutral
lipids using the oil red O dye. As shown in Figure 3c, there
was a significant accumulation of neutral lipids, which was
detected as an increased intracellular red stain after 3 days of
cisplatin treatment when compared to control mice. This
accumulation of neutral lipids was predominantly present in
the region corresponding to the proximal tubules in the
kidney cortex. Pretreatment of mice with PPARa ligand WY
alone did not have a significant effect on neutral lipid
staining (Figure 3b), but prevented the accumulation of
neutral lipids induced by cisplatin as shown in Figure 3d.
Metabolic changes in urine samples by 1H-NMR
Figure 4 shows representative spectra from the urine of the
same mouse obtained befor dosing, and for 3 days following
injection with 20 mg/kg body weight (BW) cisplatin. Visual
inspection of the spectra shows changes in various urine
metabolites after the mouse had been given a dose of
cisplatin, including increases in glucose, lactate, pyruvate,
and 2-oxoglutarate 48 h postdosing. Principal component
analysis (PCA) of the spectra integrals showed distinct
clusters for control urine and for urine collected on days 1, 2,
and 3 after cisplatin injection, indicating clear differences
Cis 3 days WY+Cis 3 days
WYControl
a b
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Figure 3 | Effect of fibrate (WY) and cisplatin on neutral lipid
accumulation. Mouse kidney frozen sections were obtained from
animals subjected to four experimental conditions, processed, and
stained with oil red O dye as described in Materials and Methods.
Depicted are the pictures obtained from oil red O staining of kidney
sections from (a) control, (b) WY-treated, (c) cisplatin, and
(d) WYþ ciplatin-treated mice.
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Figure 4 | Representative 1D 1H NMR spectra of C) control (C) and
following administration of cisplatin (D1) 24 h, (D2) 48 h
postdosing, and (D3) 72 h postdosing.
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Figure 5 | Principal component (PC) scores plot showing the
changes from control over a 72 h period following administration
of cisplatin.
2196 Kidney International (2006) 69, 2194–2204
o r i g i n a l a r t i c l e D Portilla et al.: Metabolic biomarkers of ARF
between the metabolic profiles, as shown in Figure 5. The
loadings plot (data not shown) indicated that increases in
chemical shifts resonance associated with 2-oxoglutarate, and
creatinine were the major metabolites separating day 1
samples from control, whereas increases in the glucose and
lactate chemical shift resonances drove the clustering of the
day 2 and day 3 urine samples away from control samples.
Metabolite analysis of the spectra showed that the concen-
tration of 2-oxoglutarate increased over the first 48 h after
dosing followed by a decrease from 48 to 72 h. Using PCA
analysis, we were able to show differences in metabolic
profiles not only between different days after cisplatin
injection but also between the different study groups on
the same day. Figure 6 shows the three-dimensional PCA plot
obtained from analysis of day 2 urine samples from four
groups of four mice each. These groups included control
mice shown in blue, mice administered a single dose of
cisplatin shown in red, and two groups, one maintained on a
special diet of WY-14643 alone and the other one maintained
in the fibrate diet for 7 days before cisplatin injection shown
in yellow and green, respectively. The PCA plot shows that
the four groups separate into distinct clusters, with the
control group on the special diet clustered fairly close to the
control group on a normal diet. The cisplatin group clustered
below the three groups along the PC3 axis. Metabolite
analysis shown in Table 1 indicated that cisplatin treatment
for 2 days induced significant changes in the urine levels of
glucose (200 fold increase), alanine (12-fold increase), lactate
(fourfold increase), leucine (sevenfold increase), methionine
(fourfold increase), 2-oxoglutarate (twofold increase), pyru-
vate (3.5-fold increase), and valine (eightfold increase).
Pretreatment with the diet containing PPARa ligand WY
provided protection from the metabolic changes induced by
cisplatin by reducing the increased urine levels of glucose,
lactate, methionine, oxoglutarate, and pyruvate. The data also
indicate that the PPARa ligand provided changes in urine
levels of amino acids proline and tyrosine when compared to
control or saline-treated mice. In addition, metabolite
analysis showed that 1-methylnicotinamide was elevated in
both groups maintained on the diet containing PPARa ligand
WY-16463. This metabolite has recently been shown to be a
biomarker for peroxisome proliferation.26
Biochemical measurements of glucose, NEFA, and TG
Cisplatin increases nonesterified fatty acids in serum, urine,
and kidney tissue. As neutral lipid accumulation detected by
oil red O stain represents the accumulation of NEFA, TG,
diglycerides, and cholesterol esters, we next examined
specifically the effects of cisplatin on NEFA levels measured
in serum, urine, and kidney tissue. As shown in Figure 7a,
cisplatin-treated mice exhibited a time-dependent increase in
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Figure 6 | 3D Principal component (PC) scores plot indicating the
effects of the PPARa ligand (WY) on cisplatin-induced ARF.
Table 1 | Select urine metabolite concentrations measured by 1H NMR spectroscopy and normalized to the concentration
of creatinine in the urine
Metabolite Control, n=7 Cisplatin day 2, n=7 WY, n=7 WyWY7cisplatin day 2, n=7
Alanine 0.0270.02 0.2570.13* 0.0770.06 0.1970.16*
P=0.003 P=0.037
Glucose 0.3070.30 60.98734.82* 0.6670.61 18.08723.98
P=0.004
Lactate 0.2170.30 0.8970.95 0.4370.37 0.5770.31
Leucine 0.0370.02 0.2270.10* 0.0470.01 0.2870.36
P=0.004
Methionine 0.0370.01 0.1370.07* 0.0270.01 0.0570.07
P=0.009
1-Methylnicotinamide 0.1170.06 0.0770.02 0.2470.12* 0.2270.08*
P=0.038 P=0.016
2-Oxoglutarate 7.9775.37 15.7972.78* 15.6073.76* 6.7773.21
P=0.008 P=0.010
Proline 0.2670.18 0.4170.22 0.4670.42 0.5070.41
Pyruvate 0.1270.07 0.4470.21* 0.2270.08* 0.2770.18
P=0.008 P=0.043
Trimethylamine 0.9070.89 0.2870.26 0.0770.06* 0.1070.09
P=0.048
Tyrosine 0.1770.08 0.1570.06 0.5070.56 0.4170.39
Valine 0.0270.01 0.1670.09* 0.0270.01 0.2570.36
P=0.006
Values are reported as mg metabolite/mg creatinine.
NMR, nuclear magnetic resonance.
*P-values.
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NEFA levels not only in serum and urine but also in kidney
tissue. At day 3, there was a threefold increase in serum levels,
and also at day 3 after cisplatin injection, there was a
sevenfold increase in kidney tissue levels of NEFA. Our assay
did not detect NEFA in the urine samples obtained from
saline-treated mice. However, in cisplatin-treated mice, there
was a detectable level of NEFA in the urine obtained at day 3
after cisplatin injection (0.1570.01 mEq/l/mg protein).
PPARa ligand prevents cisplatin-induced accumulation of
NEFA. Our most recent studies have shown that the use of
PPARa ligands prevents the development of cisplatin-
induced proximal tubule cell death by preventing the
inhibition of fatty acid oxidation.18 Therefore, we examined
the effect of PPARa ligand on cisplatin induced increased
NEFA levels in serum, urine, and kidney tissue. At day 3 after
cisplatin injection, there was a threefold increase in the serum
levels of NEFA. In contrast, the group of mice that received
the diet containing PPARa ligand and cisplatin exhibited
comparable levels of serum NEFA to the mice treated with
saline alone, as shown in Figure 7b. We also measured NEFA
levels in urine samples of mice treated with PPARa ligand
and cisplatin, and again similarly to saline-treated mice, we
were not able to detect measurable amounts of NEFA in the
urine samples from these mice. We next examined the effect
of PPARa ligand on cisplatin-mediated accumulation of
NEFA in kidney tissue. In the group of mice that received the
diet containing PPARa ligand and cisplatin, there was a 65%
reduction in the levels of NEFA in kidney tissue, when
compared to cisplatin-treated mice (Figure 7b).
Cisplatin increases triglyceride levels in serum and kidney
tissue. As TG represents the major component of neutral
lipids in kidney tissue, we measured TG levels in serum,
urine, and kidney tissue homogenates of mice treated with
saline (control) and mice treated with cisplatin. As shown in
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Figure 7 | Effect of cisplatin on NEFA levels in serum, urine, and
kidney tissue. Mice were administered saline (control) or cisplatin
(20 mg/kg BW) by a single intraperitoneal injection. (a) NEFA levels
were measured at days 1, 2, and 3 after cisplatin injection in serum,
urine, and kidney tissue homogenates as described in Materials and
Methods. Bars correspond to means7s.e. of at least six independent
experiments under each condition. *Po0.05, compared with control
by unpaired Student’s t-test. (b) Effect of cisplatin and fibrate (WY) on
NEFA levels. Wild-type mice were fed with either a regular or WY-
containing diet and then were given saline (control and WY groups)
or cisplatin (cisplatin and cisplatinþWY groups). NEFA levels were
measured at day 3 after cisplatin injection in serum, urine, and kidney
tissue homogenates as described in Materials and Methods Results
are expressed as the means7s.e. wPo0.05 compared to cisplatin;
*Po0.05 compared with control by unpaired Student’s t-test.
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Figure 8 | Effect of cisplatin on TG levels in serum, urine, and
kidney tissue. Mice were administered saline (control) or cisplatin
(20 mg/kg BW) by a single intraperitoneal injection. (a) TG levels were
measured in serum, urine, and kidney tissues at days 1, 2, and 3 after
cisplatin injection as described in Materials and Methods. Bars
correspond to means7s.e. of at least six independent experiments
under each condition. **Po0.005 compared with control by unpaired
Student’s t-test. (b) Effect of cisplatin and fibrate (WY) on TG levels.
Wild-type mice were fed with either a regular diet or WY-containing
diet and then were given saline (control and WY groups) or cisplatin
(cisplatin and cisplatinþWY groups). TG levels were measured in the
serum, and kidney tissue homogenates at day 3 after cisplatin
injection as described in Materials and Methods. Results are
expressed as the means7s.e. wPo0.05 compared to cisplatin;
*Po0.05, **Po0.005 compared with control by unpaired Student’s
t-test.
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Figure 8a, we were able to measure TG levels only in the
serum and kidney tissue homogenates. Our assay was not
able to detect measurable amounts of TG in urine samples
obtained from control or cisplatin-treated mice. As shown in
Figure 8a, cisplatin-treated mice exhibited a time-dependent
increase in TG levels in serum, but also in kidney tissue. At
day 3, there was a threefold increase in serum TG levels, and
also at day 3 after cisplatin injection, there was a sixfold
increase in TG levels in kidney tissue homogenates.
PPARa ligand prevents cisplatin-induced accumulation of
TGs. We next examined the effect of PPARa ligand on
cisplatin-mediated increased levels of TG in serum and
kidney tissue. At day 3 after cisplatin injection, there was a
threefold increase in the serum levels of TG. In contrast, the
group of mice that received the diet containing PPARa ligand
and cisplatin exhibited a 70% reduction in serum TG levels
when compared to cisplatin-treated mice, as shown in Figure
8b. We also examined the effect of PPARa ligand on cisplatin-
mediated accumulation of TG in kidney tissue. In the group
of mice that received the diet containing PPARa ligand and
cisplatin, there was a 55% reduction in TG levels in kidney
tissue when compared to cisplatin-treated mice. These results
are shown in Figure 8b.
Cisplatin-induced hyperglycemia and glucosuria precede
cisplatin induced ARF. 1H-NMR analysis of urine samples
revealed that glucose was present within the first 24–48 h
postinjection of cisplatin. Therefore, to corroborate these
findings, we next measured glucose levels in serum, urine,
and kidney tissue by an enzymatic colorimetric assay as
described in the Materials and Methods section. As shown in
Figure 9a, cisplatininduced time-dependent increase in
glucose levels in serum, urine, and kidney tissue. At day 3
after cisplatin injection, there was a 3.5-fold increase in serum
glucose levels when compared to saline-treated mice.
Cisplatin-treated mice also exhibited a remarkable 75-fold
increase in urine glucose levels, and a 2.5-fold increase in
kidney tissue levels of glucose, when compared to saline-
treated mice.
PPARa ligand prevents cisplatin-induced hyperglycemia and
glucosuria. Our most recent studies have shown that the use
of PPARa ligands prevent the development of proximal
tubule cell death during ARF by preserving not only fatty
acid oxidation but also by preventing the inhibition of PDC
activity in the mitochondria.18 In addition to its stimulation
of fatty acid oxidation and antiapoptotic effects, recent
reports suggest that PPARa may also play a role in the
regulation of metabolic abnormalities associated with the
metabolic syndrome.22 Therefore, we examined the effect of
PPARa ligand on cisplatin-induced increased levels of glucose
in serum, urine, and kidney tissue. As shown in Figure 9b,
serum glucose levels of wild-type mice receiving a regular diet
were significantly increased by cisplatin treatment. At day 3,
there was a 3.5-fold increase in serum glucose levels. By
contrast, cisplatin-treated mice receiving a PPARa ligand in
their diet, exhibited comparable levels of serum glucose to the
mice treated with saline alone. Similarly to our NMR results,
our biochemical analysis confirmed that cisplatin-treated
mice exhibited remarkable increases in urine glucose levels
(75-fold) when compared to saline-treated mice. In the group
of mice that received the diet containing PPARa ligand and
cisplatin, there was a 78% reduction in urine glucose levels
when compared to cisplatin-treated mice.
We next examined the effect of PPARa ligand on cisplatin-
mediated accumulation of glucose in kidney tissue. In the
group of mice that received the diet containing PPARa ligand
and cisplatin, there was a 70% reduction in glucose levels in
kidney tissue homogenates, when compared to cisplatin-
treated mice (Figure 9b).
Effect of cisplatin and fibrate (WY) on serum levels of
Insulin. In the next series of experiments, we measured the
effects of cisplatin on serum insulin levels. Three days after
one single injection of cisplatin, there were significant
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Figure 9 | Effect of cisplatin on glucose levels in serum, urine, and
kidney tissue. Mice were administered saline (control) or cisplatin
(20 mg/kg BW) by a single intraperitoneal injection. (a) Glucose levels
were measured at days 1–3 after cisplatin injection in serum, urine,
and kidney tissue homogenates as described in Materials and
Methods. Bars correspond to means7s.e. of at least six independent
experiments under each condition. *Po0.05, **Po0.005 compared
with control by unpaired Student’s t-test. (b) Effect of cisplatin and
fibrate (WY) on glucose levels. Wild-type mice were fed with either a
regular or WY-containing diet, and then were given saline (control
and WY groups) or cisplatin (cisplatin and cisplatinþWY groups).
Glucose levels were measured at day 3 after cisplatin injection in
serum, urine, and kidney tissue homogenates as described in
Materials and Methods Results are expressed as the means7s.e.
wPo0.05 compared to cisplatin; *Po0.05, **Po0.005 compared with
control by unpaired Student’s t-test.
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increases in serum insulin levels from control or saline-
treated mice of 0.50670.11 to 0.92670.14 mg/l (N¼ 6,
Po0.05). By contrast, cisplatin-treated mice receiving the
diet containing PPARa ligand exhibited comparable levels of
insulin to the mice-treated with saline alone as shown in
Table 2.
DISCUSSION
Cisplatin induces a Fanconi-like syndrome
In the present study, we find that cisplatin-induced ARF
produces an endogenous metabolic profile revealed by 1H-
NMR analysis of urine. As indicated in Table 1, the most
marked changes induced by cisplatin, and revealed by NMR
spectroscopy, occurred within the first 48 h, and were
characterized by increased concentrations of glucose, lactate,
amino acids such as alanine, valine, leucine, methionine, and
the presence of trichloroacetic acid cycle metabolites such as
pyruvate and lactate in urine. Our results validate previous
studies where quantitative changes by NMR spectroscopic
metabolite patterns provided information on the location
and severity of toxic lesions. These studies detected the
presence of glucosuria and aminoaciduria after exposure to
known proximal tubule nephrotoxins such as gentamicin,
mercuric chloride, and D-serine.27–29 The amino-acid profile
present in the urine of cisplatin-treated mice was unique and
preceded the elevations in serum creatinine.
Our study suggests that at day 2, cisplatin-induced
aminoaciduria could be explained by effects of cisplatin on:
(1) neutral amino-acid transporter SAT1-3 or system A
transporter, with reduced reabsorption of alanine, (2) the
branched chain glycoprotein-associated AA transporter
LAT-1 or system L transporter, with reduced reabsorption
of leucine and valine, and (3) the pH-dependent and
sodium-independent Hþ /AA transport, with reduced reab-
sorption of proline. We did not detect by NMR increases in
basic amino acids in the urine such as cysteine, which has
been described before in the inherited or acquired forms of
the De Toni–Fanconi syndrome. As more than 90% of the
amino-acid transport occurs in the proximal convoluted
tubule ,30,31 our study suggests that in addition to its
cytotoxic effect on the S3 segment of the proximal tubule as
shown in our electron microscopic data at day 3, cisplatin has
a toxic effect on the reabsorption of amino acids on the
proximal convoluted tubule.
Glucosuria, and enhanced excretion of amino acids, are
both strong indicators of proximal tubule injury in general,
likely caused by impaired tubular reabsorption in the
proximal tubule via sodium-dependent glucose transport.
In the case of gentamicin, recent in vitro and in vivo studies
performed in LLCPK1 cells, as well as in mouse kidney tissue,
have shown that aminoglycoside antibiotics reduce glucose
reabsorption in kidney tissue by reducing mRNA, protein
expression, and function of the sodium-dependent glucose
transporter, which are located in the apical membrane of the
proximal tubule.32 Our most recent unpublished studies,
using alpha-D-14C-glucopyranoside to examine the effects of
cisplatin on glucose uptake in LLCPK1 cells also lend support
to the hypothesis that the inhibition of sodium-dependent
glucose transport represents an early intracellular event,
which precedes proximal tubule cell death when LLCPK1 cells
are exposed to cisplatin. Therefore, it is quite possible that a
common mechanism of proximal tubule nephrotoxicicy for
both gentamicin and cisplatin relates to reduced expression
and function of sodium-dependent glucose transporters. This
mechanism of proximal tubule nephrotoxicity explains our
findings by NMR analysis of the early presence of glucosuria
and amino-aciduria in cisplatin-treated mice.
Cisplatin-induced hyperglycemia and glucose accumulation
in kidney tissue are prevented by PPARa ligand
Previous studies carried out in rats have shown that
cisplatin-induced hyperglycemia is secondary to the presence
of marked glucose intolerance, in association with an
impaired insulin response, and abnormal glucagon response
to a glucose stimulus.33,34 Our studies corroborate those
previous findings in mice treated with cisplatin, including
the presence of severe hyperglycemia, as well as the presence
of hyperinsulinemia, as shown in Table 2. In addition,
our studies also confirmed the presence of an in-
appropriate insulin response when compared to the level of
hyperglycemia induced by cisplatin in these mice. On the
other hand, fibrate treatment significantly ameliorated
cisplatin-induced hyperglycemia and hyperinsulinemia, and
also prevented cisplatin-mediated accumulation of glucose in
kidney tissue. These results suggest that fibrate treatment
leads to an improved insulin action in kidney tissue. This
beneficial effect of fibrates or PPARa ligands on hyperglyce-
mia and insulin levels has been previously observed in
animal models of diabetes, and also in diabetes-prone
animals.35,36 Using Otsuka Long Evans Tokushima Fatty rats,
Koh et al37 have shown that fibrate treatment prevented the
development of diabetes by several mechanisms, which
Table 2 | Effect of cisplatin and fibrate (WY) on serum levels of glucose, insulin, NEFA, and TGs
Serum Control 3 Day cisplatin WY WY7Cisplatin
Glucose (mg/dl) 145.87717.00 507.33785.54** 91.2712.3 142.75726.78w
Insulin (mg/l) 0.5170.11 0.9370.14 0.3770.28 0.3370.11
NEFA (mEq/l) 0.1170.02 0.3670.05* 0.0670.02 0.1170.04w
TG (mg/dl) 25.3371.45 79.0079.46** 22.3370.33 42.3375.81*,w
Results are expressed as the means7s.e. wPo0.05 compared to cisplatin, *Po0.05, **Po0.005 compared with control by unpaired Student’s t-test.
NEFA, nonesterified fatty acid; TGs, triglyceride.
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included: (1) reduced basal plasma insulin concentrations,
(2) reduced adiposity, (3) improved peripheral insulin action,
and (4) by exerting beneficial effects on pancreatic b-cell
function.
Cisplatin-mediated renal lipid accumulation is ameliorated
by PPARa ligand
One previous study had reported that cisplatin nephrotoxi-
city in rats was accompanied by significant elevations in
serum total cholesterol and TG concentrations, an effect that
was not accompanied by injury to the liver.38 Our results
extend those previous observations showing also accumula-
tion of TG and NEFA in kidney tissue of cisplatin-treated
mice. The mechanisms by which cisplatin increases both
NEFA and TG accumulation in kidney tissue likely reflect in
part cisplatin-mediated inhibition of fatty acid oxidation. We
have shown that cisplatin causes a significant reduction in
mRNA levels and enzyme activity of mitochondrial medium
chain acyl-CoA dehydrogenase, and that the use of PPARa
ligand WY prevented cisplatin-induced reduction of mRNA
levels and enzyme activity of mitochondrial medium chain
acyl-CoA dehydrogenase and ameliorated ARF.18 By contrast,
cisplatin-treated PPARa-null mice fail to demonstrate a
protective effect of fibrate treatment, and do not reverse
cisplatin-mediated inhibition of mitochondrial medium
chain acyl-CoA dehydrogenase.18 In our most recent study
carried out in renal epithelial cells in culture,21 we found that
cisplatin directly inhibited PPARa activity in these cells, and
this event was accompanied by increased accumulation of
NEFA. Pretreatment with fibrate prevented the inhibition of
PPARa activity, and the accumulation of NEFA, and also did
prevent cisplatin-induced proximal tubule cell death, sup-
porting our in vivo observations about the protective role of
PPARa ligands in reducing accumulation of NEFA and
preventing cisplatin-mediated nephrotoxicity.
In addition to the protective effects of fibrates on
preventing cisplatin-mediated inhibition of fatty acid oxi-
dation in kidney tissue, our study cannot rule out the
presence of protective systemic effects of fibrates on kidney
tissue lipotoxicity. For example, the most pronounced
systemic effect of fibrates is to reduce plasma TG-rich
lipoproteins. The hypotriglyceridemic action of fibrates
involves combined effects on lipoprotein lipase and apo-CIII
expression,39 resulting in increased lipolysis. The induction of
lipoprotein lipase expression occurs at the transcriptional
level and is mediated by PPARa. In contrast to lipoprotein
lipase, transcription of the apoCIII gene is inhibited by
fibrates, resulting in decreased production of apoCIII in the
liver and reduced serum TG levels.40 The repression of
apoCIII gene expression by fibrates is mediated by PPARa.41
Previous studies have also shown that in addition to
increased lipolysis, fibrates also increase the hepatic uptake
of free fatty acids by inducing the expression of specific fatty
acid transport proteins and by increasing the formation of
acyl CoA esters by acyl CoA synthetase.42 Therefore, fibrates
could potentially change free fatty acid metabolism from TG
synthesis to catabolism. Additional cellular mechanisms by
which cisplatin increases the accumulation of TG in the
proximal tubule are likely to be involved. In a recent study by
Johnson et al.,43 the authors examined the potential
mechanisms by which proximal tubule injury leads to TG
accumulation. Significant differences in the expression and
function of TG synthetic and degradative pathways were
found, depending on the in vivo or in vitro model of tubular
cell damage used. A significant increased expression in acyl
CoA: diacylglycerol acyltransferase expression was seen in the
antimycin and endotoxin models, whereas reduced expres-
sion of TG lipase was seen in the glycerol model of ARF.
Although we have not examined in detail the cellular
mechanisms by which cisplatin induces TG accumulation
in the proximal tubule, our recent gene array analysis of
kidney tissue of mice treated with cisplatin show that mRNA
levels of fatty acid synthetase gene were significantly reduced
by cisplatin. This observation suggests that reduced TG
catabolism by cisplatin, in addition to increased accumula-
tion of free fatty acids, represent important mechanism(s) of
TG accumulation in the proximal tubule.
The protective effects of fibrates on cisplatin-mediated
ARF could also be related to improved endothelial dysfunc-
tion. Although this has not been characterized in the cisplatin
model of acute kidney injury, PPARa ligands have been
shown to have an effect in the vascular endothelium.44 Using
the model of acute myocardial infarction, fenofibrate
treatment was shown to reduce myocardial infarction, size,
and improved postischemic contractile dysfunction. Hearts
from PPARa-null mice exhibited increased susceptibility to
ischemic damages and were refractory to protection by
fenofibrate treatment, suggesting that the beneficial effects of
fenofibrate were mediated via PPARa. Furthermore, feno-
fibrate improved endothelium- and nitric oxide-mediated
vasodilatation in aorta and mesenteric vascular bed. Alto-
gether, these data in heart tissue suggest that fenofibrate
exerts cardioprotective effects and improves nitric oxide-
mediated response probably by enhancing antioxidant
capacity of the vessel wall.44
In summary, our analysis by NMR spectroscopy demon-
strates that exposure to cisplatin results in a marked change
in the urinary metabolic profile that precedes changes in
known biomarkers of nephrotoxicity, such as BUN and
serum creatinine. Future analysis by high performance liquid
chronalography-mass spectrometry based techniques should
allow us to further differentiate the presence of spurious
markers that merely reflect the administration of cisplatin,
from genuine biomarkers of toxicity. In addition, our results
further support the protective role of PPARa ligands on renal
function by preventing systemic and renal alterations in
glucose and lipid metabolism caused by cisplatin.
MATERIALS AND METHODS
Animal model of cisplatin-induced acute renal failure
Experimental ARF was induced in 8- to 10-week-old male mice
(strain Sv129) using cisplatin administration. The animals used in
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these studies (IACUC protocol no. 2-03-1) were housed
at the Veterinary Medical Unit at the Central Arkansas Veterans
Health Care System, Little Rock, AR, USA. When appropriate,
animals were painlessly killed according to methods of euthanasia
approved by the Panel on Euthanasia of the American Veterinary
Medical Association. Animals were maintained on standard chow,
and as indicated, a group of animals was fed with a special diet
containing WY-14643 (0.1%) for 7 days before the induction of
ARF. Cisplatin was administered by a single intraperitoneal injection
of 20 mg/kg BW. After the induction of renal failure, the animals
were returned to their cages and allowed free access to food and
water. Urine samples were collected for NMR analysis and
biochemical measurements of metabolite formation at day 1, 2,
and 3 after cisplatin administration. Blood was drawn by retro-
orbital bleeding at the time of killing and the kidneys were
harvested. For in situ lipid accumulation analysis, kidneys were
snap-frozen in liquid nitrogen. Thin sections (6–8 mm) were cut in a
cryostat and stained with oil red O. For biochemical analyses
(glucose, NEFA, TG) kidneys were snap-frozen in liquid nitrogen
and stored at 801C until used.
Electron microscopy
Animals subjected to four experimental conditions, saline
(control), cisplatin, fibrate, and fibrateþ cisplatin, were anesthe-
tized, and the kidneys removed after fixation by vascular
perfusion through the left ventricle. Briefly, first the blood was
flushed with a small volume of saline containing heparin (5000 U/
ml), procain-HCl (1%), and CaCl2 (16%). The animals were then
intravascularly perfused with 50 ml of freshly prepared 3%
paraformaldehyde in cacodylate–sucrose buffer containing 0.06%
MgCl2, 0.5% picric acid, and 10% polyvinyl pyrrolidone. The
kidneys were then removed, cut in halves, and postperfusion fixed in
3% paraformaldehyde þ 0.1% glutaraldehyde solution, and em-
bedded in epon. One micron sections were cut and processed for
electron microscopy.
NMR Spectroscopy
Urine samples were analyzed at the National Center for Toxicolo-
gical Research on a Bruker Avance NMR spectrometer equipped
with a triple resonance HCN (hydrogen, carbon, nitrogen) cryop-
robe operating at 600.133 MHz for proton. To 80ml of urine
obtained from mice injected with cisplatin, 100 ml of sodium
phosphate buffer (pH¼ 7.4) and 20 ml of a solution of 1 mM TMSP
(sodium 3-trimethylsilyl-[2,2,3,3-d4]propionate) and 10 mM imida-
zole in D2O were added. A total of 10 mM imidazole was added as a
pH reference for metabolite identification software used later. A
standard water suppression pulse program was employed for the
presaturation of the water peak during a delay time, d1, of 2.5 s. A
total of 64 scans were collected into 32 768 data points. A spectral
width of 7309.94 Hz was utilized with an acquisition time of 2.24 s.
In the studies where the effects of PPARa ligand WY were examined,
urine samples obtained after 2 days of cisplatin injection were
analyzed, as the urine metabolic profile at this point was quite
different than the one obtained from control mice. Solutions of
100ml of urine, 80 ml sodium phosphate buffer, 20 ml of 1 mM TMSP,
and 10 mM imidazole in D2O were prepared for analysis. A standard
Bruker 1D NOESY pulse sequence was employed with suppression
of the water peak during a 2.0 s delay time, d1, and a 100 ms mixing
time. A total of 256 scans were collected into 65 536 data points. A
spectral width of 12 019.23 Hz was employed with a total acquisition
time per spectrum of 2.73 s.
NMR spectral processing
Spectra were processed using ACD/Labs 1D NMR Manager, version
9.0. All spectra were zero filled to 128K points followed by
manipulation by a 0.3 Hz line broadening factor. Spectra were then
Fourier transformed, phased using the ‘simple’ method, and baseline
corrected using the ‘SpAveraging’ method with a box half-width of
61 and noise factor of three. The ‘SpAveraging’ method first
generates a smoothed spectrum. The spectrum is then used for two
processes, baseline recognition and baseline modeling to generate
the baseline corrected spectrum. In the baseline recognition step, the
defined box half-width (rectangle of spectral width N) is used to
decide whether a point, i, belongs to baseline. The point is placed in
the middle of the rectangle and the noise factor used in order to
determine whether a point is peak or base line. The box is moved
from one data point to the next and repeated until the entire
spectrum has been analyzed. Subsequently, the baseline of the
smoothed spectrum is modeled over the noise regions in order to
generate the final baseline corrected spectrum. Finally, spectra were
autoreferenced to internal TMSP at 0.00 p.p.m. The processed
spectra from each sample set were overlaid in a window in the 1D
NMR Manager. The overlaid spectra were then integrated as a group
using the intelligent bucketing module in the ACD/Labs software
after defining regions to be excluded. These included the regions
containing the residual water peak and urea for spectra from urine
and aqueous extracts. An integration width of 0.04 p.p.m. with a
looseness of 50% was selected for integration. Therefore, the
integration bin widths were allowed to vary between 0.02 to
0.06 p.p.m. The table of integrals was exported a text file for
statistical analysis. Individual spectra were exported as jcamp files
for further analysis by Chenomx Eclipse software. Chenomx Eclipse
software (Chenomx, Edmonton, Canada) and databases were
applied for identification of specific metabolites in the spectra. All
statistical analysis of NMR spectra was carried out using Statistica
version 6.0 (Statsoft, Tulsa, OK, USA). Initially, PCA was performed
based on covariance of the intelligently bucketed intensities from the
NMR spectra.
Oil red O staining
Neutral lipid accumulation was qualitatively assessed using oil red O
stain of 10 mm frozen kidney sections obtained from control,
cisplatin-, fibrate-, and fibrateþ cisplatin-treated mice. Histophoto-
graphs were taken by digital images using a Nikon Eclipse E800
microscope.
Biochemical studies
Glucose, NEFA, and TG levels were measured in plasma and urine
samples using separate colorimetric enzyme assay kits (WAKO
Chemicals GmbH, Neuss, Germany). Mouse kidney tissue obtained
from animals subjected to four experimental conditions was
homogenized using dounce homogenizer with 50 strokes, then
briefly sonicated in phosphate-buffered saline (pH 7.4) and an
aliquot of the homogenate was saved for protein assay. After
homogeneization, kidney tissue samples were subjected to Bligh
Dyer extraction, and after centrifugation at 1000 g to separate the
aqueous and organic phases, the chloroform phase was dried under
nitrogen. Then, samples were brought up into 200 ml in a sample
buffer containing 1.3 mM Na-EDTA, 7.6 mM Na azide, 0.2% (w/v)
Triton X-100, pH 6.5, as provided by the manufacturer. Then, the
amount of NEFA was assayed enzymatically using 10 ml volumes of
sample by conversion to acetyl CoA esters using acyl CoA synthetase
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followed by oxidation of the acyl CoA by acyl CoA oxidase with the
production of hydrogen peroxide that is then measured colori-
metrically (NEFA-C kit; WAKO Chemicals). This assay detects
mostly medium and long chain, but not short chain fatty acids. TG
levels were measured in kidney tissue homogenates after lipid
extraction and using a different colorimetric assay according to the
manufacturer’s instructions. (L-Type TG H; WAKO Chemicals).
Glucose was measured in the kidney tissue homogenates using the
same colorimetric assay kit used to estimate the glucose concentra-
tions in serum and urine (glucose C2; WAKO Chemicals). In the
case of the kidney tissue, the metabolite concentrations were
normalized by the protein concentration present in the homogenate.
Plasma insulin levels were measured by enzyme-linked immuno-
sorbent assay using mouse insulin as standard and the kit provided
by Mercodia AB, Uppsala, Sweden.
Statistics analysis
Results are presented as means7s.e. Statistical analysis was
performed using unpaired Student’s t-test. A P-value of o0.05
was considered to be statistically significant.
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